Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ZTS - Zoetis Inc.


160.06
-1.620   -1.012%

Share volume: 2,652,620
Last Updated: 03-13-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.01%

PREVIOUS CLOSE
CHG
CHG%

$161.68
-1.62
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
75%
Profitability 90%
Dept financing 45%
Liquidity 75%
Performance 68%
Company vs Stock growth
vs
Performance
5 Days
-6.83%
1 Month
1.61%
3 Months
-8.96%
6 Months
-17.60%
1 Year
-7.95%
2 Year
-2.73%
Key data
Stock price
$160.06
P/E Ratio 
29.48
DAY RANGE
$159.57 - $161.59
EPS 
$4.49
52 WEEK RANGE
$144.80 - $200.33
52 WEEK CHANGE
-$7.25
MARKET CAP 
73.287 B
YIELD 
1.06%
SHARES OUTSTANDING 
453.051 M
DIVIDEND
$0.50
EX-DIVIDEND DATE
01-21-2025
NEXT EARNINGS DATE
N/A
BETA 
0.19
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,090,328
AVERAGE 30 VOLUME 
$4,050,311
Company detail
CEO: Kristin C. Peck
Region: US
Website: zoetis.com
Employees: 13,800
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts.

Recent news